Ray Dalio’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ray Dalio’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,802	Closed	-$283K	–	738
2021 Q3	$283K	Buy	+12,802	New	+$203K	﹤0.01%	640

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MAM

Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Ray Dalio's AUPH Position: Q4 2021 in Review

Ray Dalio sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 12,802 shares — an estimated $283K sold.

Ray Dalio first reported a position in AUPH in Q3 2021 and held it in 1 quarter. The position peaked at $283K in Q3 2021. 190 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

Ray Dalio reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Ray Dalio sold 12,802 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $283K.
Ray Dalio first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Ray Dalio's Aurinia Pharmaceuticals position peaked at $283K in Q3 2021.
190 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on Bridgewater Associates's 13F filing for Q4 2021, filed 14 Feb 2022.